Teva Pharmaceutical Industries Ltd. $TEVA Shares Bought by Assetmark Inc.

Assetmark Inc. lifted its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 84.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 37,054 shares of the company’s stock after acquiring an additional 16,979 shares during the period. Assetmark Inc.’s holdings in Teva Pharmaceutical Industries were worth $748,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Phoenix Financial Ltd. boosted its holdings in shares of Teva Pharmaceutical Industries by 9.4% in the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after acquiring an additional 3,533,800 shares in the last quarter. National Pension Service raised its holdings in Teva Pharmaceutical Industries by 24.2% during the third quarter. National Pension Service now owns 2,073,293 shares of the company’s stock worth $41,881,000 after purchasing an additional 404,526 shares in the last quarter. Oak Harvest Investment Services acquired a new stake in Teva Pharmaceutical Industries in the third quarter worth approximately $1,010,000. Harel Insurance Investments & Financial Services Ltd. boosted its stake in Teva Pharmaceutical Industries by 12.9% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after purchasing an additional 4,306,363 shares in the last quarter. Finally, Public Sector Pension Investment Board boosted its stake in Teva Pharmaceutical Industries by 11.5% during the 3rd quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock valued at $13,543,000 after purchasing an additional 69,000 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on TEVA shares. The Goldman Sachs Group upped their price objective on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, February 9th. Barclays boosted their price target on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. Scotiabank raised their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. JPMorgan Chase & Co. boosted their target price on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Finally, Truist Financial increased their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.56.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $34.24 on Friday. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $37.35. The company has a 50-day moving average of $32.57 and a two-hundred day moving average of $25.07. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80. The stock has a market cap of $39.37 billion, a price-to-earnings ratio of 28.53, a PEG ratio of 11.49 and a beta of 0.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The business had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same quarter in the prior year, the firm earned $0.71 EPS. The firm’s quarterly revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Mark Sabag sold 216,892 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the transaction, the insider owned 52,828 shares in the company, valued at approximately $1,517,748.44. The trade was a 80.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Richard Daniell sold 115,468 shares of the stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the sale, the vice president directly owned 48,384 shares of the company’s stock, valued at approximately $1,387,653.12. This represents a 70.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 422,060 shares of company stock worth $12,254,965. 0.49% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.